COMPANY PROFILE // THE 014 REPORT
Cocrystal Pharma, Inc.
COCP (Nasdaq) · Formerly: BIOZONE PHARMACEUTICALS, INC.; International Surf Resorts, Inc.
Assembled from 3 government sources in 0.2 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- AmberGLEIF: the direct parent is not reported; reporting exception filed with reason NON_PUBLIC.
- Amber4 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-08-18: a pattern of leadership change.
- AmberLEI 549300QCJ6RBUJKI7S66 registration status is LAPSED (last update 2023-08-04): the legal-entity record has not been renewed.
✓ SEC filings✓ LEI✓ SAM registrationpossible match✗ IRS return✗ State registration✗ Website✗ Lobbying registration
No IRS return, no state registration, no website, no lobbying registration on record.
Cocrystal Pharma, Inc. is an SEC-registered operating company in pharmaceutical preparations, incorporated in DE, based in Bothell, WA; listed as COCP (Nasdaq).[source] It has filed 50 documents with the SEC in the last 12 months; the latest is Form 10-Q, filed 2026-11-16.[source] Its largest institutional holders on 13F filings are VANGUARD CAPITAL MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, TWO SIGMA INVESTMENTS, LP (as of 2026-06-30).[source] Seraphix flags 3 items from these records: 4 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-08-18; LEI 549300QCJ6RBUJKI7S66 registration status is LAPSED (last update 2023-08-04); GLEIF.[source]
- red0
- amber3
- info0
- VANGUARD CAPITAL MANAGEMENT LLC$376K
- RENAISSANCE TECHNOLOGIES LLC$189K
- TWO SIGMA INVESTMENTS, LP$184K
- GEODE CAPITAL MANAGEMENT, LLC$80K
- BlackRock, Inc.$77K
- CITADEL ADVISORS LLC$47K
- NEUBERGER BERMAN GROUP LLC$33K
- XTX Topco Ltd$31K
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Lee Sam · President and Co-CEO (Officer) · latest Form 4 2026-01-13 · filing · LinkedIn search
- Martin James Joseph · Co-CEO and CFO (Officer) · latest Form 4 2026-01-13 · filing · LinkedIn search
- FROST PHILLIP MD ET AL · Director,10% owner · latest Form 4 2026-02-25 · filing · LinkedIn search
- Hassan Fred · Director · latest Form 4 2026-01-13 · filing · LinkedIn search
- Japour Anthony J · Director · latest Form 4 2026-01-13 · filing · LinkedIn search
- Kornberg Roger D. · Director · latest Form 4 2026-01-13 · filing · LinkedIn search
- PFENNIGER RICHARD C JR · Director · latest Form 4 2026-01-13 · filing · LinkedIn search
- Rubin Steven D · Director · latest Form 4 2026-01-13 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001412486 | source |
| LEI | 549300QCJ6RBUJKI7S66 | source |
| UEIpossible match | UY8UDESGRJ17 | source |
| CAGEpossible match | 7SGF5 | source |
| EIN | 35-2528215 | source |
| Business address (SEC) | 19805 N. CREEK PARKWAY, BOTHELL, WA, 98011 | source |
Does not exist in the records we hold: NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2019-04-02 · in -2,791 days · LEI next renewal (549300QCJ6RBUJKI7S66)
- 2026-12-11 · in 19 days · SAM registration expires (UEI UY8UDESGRJ17)possible match
- 2027-03-31 · in 129 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 174 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
ADDRESS · ZIP CODE
Location context
Federal contractors nearby in the same code (2)
- JW3 BIOTECHNOLOGIES LLC · SAM Active
- COCRYSTAL PHARMA, INC. · SAM Active
registered in SAM.gov with the same ZIP code (98011) and the same primary NAICS code (541714), extract 2026-11-01
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- BridgeBio Pharma, Inc. · Hassan Fred
- Eloxx Pharmaceuticals, Inc. · Rubin Steven D
- Entera Bio Ltd. · Rubin Steven D
- EoCene Ltd. · Brosgart Carol L
- EyePoint, Inc. · Hassan Fred
- Fluent, Inc. · PFENNIGER RICHARD C JR
- GeneDx Holdings Corp. · PFENNIGER RICHARD C JR
- Inmune Bio Inc. · SAPIRSTEIN JAMES
- NOCOPI TECHNOLOGIES INC/MD/ · FROST PHILLIP MD ET AL
- Niagen Bioscience, Inc. · Rubin Steven D
- Opko Health, Inc. · FROST PHILLIP MD ET AL
- Opko Health, Inc. · PFENNIGER RICHARD C JR
- Opko Health, Inc. · Rubin Steven D
- PRECIGEN, INC. · Hassan Fred
- RECURSION PHARMACEUTICALS, INC. · Hassan Fred
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-12-11 registration SAM registration expiry (UEI UY8UDESGRJ17) · SAM.gov
- 2026-11-16 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-06 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-09-09 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-08-18 officer change 8-K items 5.02,9.01 · SEC EDGAR
- 2026-08-17 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-08-13 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-07 filing SCHEDULE 13D · SEC EDGAR
- 2026-08-07 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-08-03 filing 8-K items 1.01,3.02,7.01,9.01 · SEC EDGAR
- 2026-07-17 filing 8-K items 5.07 · SEC EDGAR
- 2026-06-09 officer change 8-K items 5.02,9.01 · SEC EDGAR
- 2026-06-03 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-05-27 filing DEFA14A · SEC EDGAR
- 2026-05-27 filing Proxy statement · SEC EDGAR
- 2026-05-26 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-05-15 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-01 filing EFFECT · SEC EDGAR
- 2026-04-30 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-04-29 filing CORRESP · SEC EDGAR
- 2026-04-28 filing UPLOAD · SEC EDGAR
- 2026-04-23 filing S-3 · SEC EDGAR
- 2026-04-02 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-03-31 filing Annual report (10-K) · SEC EDGAR
- 2026-03-31 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-03-13 officer change 8-K items 5.02 · SEC EDGAR
- 2026-03-09 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-02-19 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-01-15 officer change 8-K items 5.02 · SEC EDGAR
- 2026-01-13 insider First Form 3/4/5 on record for Lee Sam (President and Co-CEO) · SEC Forms 3/4/5
170 earlier entries
- 2026-01-13 insider First Form 3/4/5 on record for Japour Anthony J (Director)
- 2026-01-13 insider First Form 3/4/5 on record for Kornberg Roger D. (Director)
- 2026-01-13 insider First Form 3/4/5 on record for Rubin Steven D (Director)
- 2025-12-18 filing 8-K items 7.01,9.01
- 2025-12-01 filing 8-K items 7.01,9.01
- 2025-11-14 filing 8-K items 2.02,9.01
- 2025-11-14 filing Quarterly report (10-Q)
- 2025-10-30 filing SCHEDULE 13D/A
- 2025-10-30 filing 8-K items 1.01,3.02,7.01,9.01
- 2025-10-30 insider First Form 3/4/5 on record for Martin James Joseph (Co-CEO and CFO)
- 2025-10-30 insider First Form 3/4/5 on record for FROST PHILLIP MD ET AL (Director,10% owner)
- 2025-10-30 insider First Form 3/4/5 on record for Hassan Fred (Director)
- 2025-10-30 insider First Form 3/4/5 on record for PFENNIGER RICHARD C JR (Director)
- 2025-10-27 filing 8-K items 7.01,9.01
- 2025-10-02 filing SCHEDULE 13D/A
- 2025-09-29 filing 424B3
- 2025-09-25 filing EFFECT
- 2025-09-25 filing CORRESP
- 2025-09-24 filing UPLOAD
- 2025-09-19 filing Registration (S-1)
- 2025-09-15 filing 8-K items 1.01,3.02,7.01,9.01
- 2025-09-15 filing 424B5
- 2025-09-12 filing 8-K items 7.01,9.01
- 2025-09-12 filing 8-K items 7.01,9.01
- 2025-09-12 filing 424B3
- 2025-08-28 filing UPLOAD
- 2025-08-14 filing Quarterly report (10-Q)
- 2025-08-14 filing 8-K items 2.02,9.01
- 2025-08-13 filing CORRESP
- 2025-08-05 filing 8-K items 7.01,9.01
- 2025-07-30 filing UPLOAD
- 2025-07-10 filing 8-K items 7.01,9.01
- 2025-07-01 filing 8-K items 5.07
- 2025-06-18 filing 8-K items 5.03,9.01
- 2025-06-05 filing 8-K items 7.01,9.01
- 2025-05-29 filing 8-K items 7.01,9.01
- 2025-05-15 filing 8-K items 2.02,9.01
- 2025-05-15 filing Quarterly report (10-Q)
- 2025-05-05 filing DEFA14A
- 2025-05-05 filing Proxy statement
- 2025-04-25 filing PRE 14A
- 2025-04-24 filing 8-K items 7.01,9.01
- 2025-04-23 filing 8-K items 7.01,9.01
- 2025-04-08 officer change 8-K items 5.02,9.01
- 2025-04-01 filing 8-K items 8.01,9.01
- 2025-03-31 filing Annual report (10-K)
- 2025-03-31 filing 8-K items 2.02,9.01
- 2025-01-13 filing 8-K items 7.01,9.01
- 2025-01-08 filing 8-K items 7.01,9.01
- 2024-12-31 filing 8-K items 7.01,9.01
- 2024-11-13 filing 8-K items 2.02,9.01
- 2024-11-13 filing Quarterly report (10-Q)
- 2024-10-31 filing 8-K items 7.01,9.01
- 2024-10-10 officer change 8-K items 5.02
- 2024-08-20 filing 8-K items 7.01,9.01
- 2024-08-14 filing 8-K items 2.02,9.01
- 2024-08-14 filing Quarterly report (10-Q)
- 2024-07-18 filing 8-K items 7.01,9.01
- 2024-06-28 filing 8-K items 5.03,5.07,9.01
- 2024-06-20 filing 8-K items 7.01,9.01
- 2024-05-13 filing 8-K items 2.02,9.01
- 2024-05-13 filing Quarterly report (10-Q)
- 2024-05-07 filing Proxy statement
- 2024-05-01 filing 8-K items 7.01,9.01
- 2024-04-26 filing PRE 14A
- 2024-04-17 filing 10-K/A
- 2024-03-28 filing Annual report (10-K)
- 2024-03-28 filing 8-K items 2.02,9.01
- 2024-03-19 filing 8-K items 7.01,9.01
- 2024-03-01 filing 8-K items 1.02,9.01
- 2024-01-08 filing 8-K items 7.01,9.01
- 2024-01-04 filing 8-K items 7.01,9.01
- 2023-12-21 filing 8-K items 1.02,9.01
- 2023-12-06 filing 8-K items 7.01,9.01
- 2023-12-04 filing 8-K items 7.01,9.01
- 2023-11-29 filing 8-K items 7.01,9.01
- 2023-11-13 filing 8-K items 2.02,9.01
- 2023-11-13 filing Quarterly report (10-Q)
- 2023-10-31 filing 8-K items 7.01,9.01
- 2023-08-16 filing 8-K items 2.02,9.01
- 2023-08-14 filing Quarterly report (10-Q)
- 2023-06-15 filing 8-K items 8.01,9.01
- 2023-06-15 filing 424B5
- 2023-06-12 filing 8-K items 5.07
- 2023-05-26 filing EFFECT
- 2023-05-24 filing CORRESP
- 2023-05-24 filing S-3/A
- 2023-05-19 filing UPLOAD
- 2023-05-15 filing Quarterly report (10-Q)
- 2023-05-15 filing 8-K items 2.02,9.01
- 2023-05-12 filing S-3
- 2023-04-28 filing Proxy statement
- 2023-04-24 officer change 8-K items 5.02,7.01,9.01
- 2023-04-14 filing SC 13D/A
- 2023-04-10 filing 8-K items 1.01,3.02,7.01,9.01
- 2023-04-04 filing 8-K items 8.01,9.01
- 2023-03-29 filing Annual report (10-K)
- 2023-03-15 filing 8-K items 7.01,9.01
- 2023-01-09 filing 8-K items 7.01,9.01
- 2022-11-14 filing Quarterly report (10-Q)
- 2022-10-26 filing 8-K items 3.01,7.01,9.01
- 2022-10-03 filing 8-K items 5.03,9.01
- 2022-09-12 filing 8-K items 7.01,9.01
- 2022-08-15 filing Quarterly report (10-Q)
- 2022-08-15 filing 8-K items 2.02,9.01
- 2022-07-29 officer change 8-K items 5.02
- 2022-05-20 filing 8-K items 5.07
- 2022-05-19 filing 8-K items 3.01
- 2022-05-11 filing Quarterly report (10-Q)
- 2022-05-11 filing 8-K items 2.02,9.01
- 2022-04-11 filing Proxy statement
- 2022-04-01 filing PRE 14A
- 2022-03-23 filing Annual report (10-K)
- 2022-03-23 filing 8-K items 2.02,9.01
- 2021-12-22 filing 8-K items 7.01,9.01
- 2021-11-19 filing 8-K items 3.01
- 2021-11-15 filing Quarterly report (10-Q)
- 2021-11-15 filing 8-K items 2.02,9.01
- 2021-09-14 filing 8-K items 7.01,9.01
- 2021-08-16 filing Quarterly report (10-Q)
- 2021-07-20 officer change 8-K items 5.02
- 2021-07-12 filing 8-K items 7.01,9.01
- 2021-06-21 officer change 8-K items 5.02,5.07
- 2021-06-10 filing SC 13D/A
- 2021-06-07 filing DEFA14A
- 2021-06-01 filing DEFA14A
- 2021-05-28 filing DEFA14A
- 2021-05-28 officer change 8-K items 5.02,9.01
- 2021-05-25 filing SC 13D
- 2021-05-17 filing Quarterly report (10-Q)
- 2021-05-05 filing 8-K items 1.01,9.01
- 2021-05-05 filing 424B5
- 2021-05-05 filing 8-K items 8.01,9.01
- 2021-04-26 filing DEFA14A
- 2021-04-26 filing Proxy statement
- 2021-04-16 filing PRE 14A
- 2021-03-17 filing Annual report (10-K)
- 2021-03-09 filing 8-K items 7.01,9.01
- 2021-02-19 filing 8-K items 5.03,9.01
- 2021-01-21 filing 8-K items 7.01,9.01
- 2021-01-11 filing 8-K items 7.01,9.01
- 2020-12-18 filing 8-K items 8.01
- 2020-11-19 filing SC 13D/A
- 2020-11-13 filing Quarterly report (10-Q)
- 2020-11-06 filing 8-K items 3.01
- 2020-10-02 filing 8-K items 8.01,9.01
- 2020-08-27 filing 8-K items 1.01,9.01
- 2020-08-27 filing 424B5
- 2020-08-27 filing 8-K items 8.01,9.01
- 2020-08-27 filing 8-K items 8.01,9.01
- 2020-08-26 filing 424B5
- 2020-08-06 filing Quarterly report (10-Q)
- 2020-07-02 filing 8-K items 1.01,9.01
- 2020-07-01 filing 424B5
- 2020-06-26 officer change 8-K items 5.02
- 2020-06-15 filing 8-K items 5.07
- 2020-06-08 filing 8-K items 1.02
- 2020-05-13 filing EFFECT
- 2020-05-13 filing Quarterly report (10-Q)
- 2020-05-12 filing CORRESP
- 2020-05-11 filing CORRESP
- 2020-05-11 filing 8-K items 7.01,9.01
- 2020-05-04 filing S-3/A
- 2020-05-04 filing CORRESP
- 2020-04-28 filing DEFA14A
- 2020-04-28 filing Proxy statement
- 2020-04-27 filing UPLOAD
- 2020-04-22 filing 8-K items 1.01,7.01,9.01
- 2020-04-20 officer change 8-K items 5.02,9.01
- 2020-04-17 filing S-3
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-16 (within 7 days) 10-Q filed
- 2026-09-09 (older) 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-18 (older) 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-08-17 (older) 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-13 (older) 10-Q filed
- 2026-08-03 (older) 8-K filed: Item 1.01 material agreement; Item 3.02 unregistered equity sale; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-07-17 (older) 8-K filed: Item 5.07 shareholder vote
- 2026-06-09 (older) 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-21; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:COCP The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
2 possible matches held apart, matched by name only, not counted above; 1 record under a former name, shown apart.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1412486 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | COCP / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| LEI (root of the ownership tree) | 549300QCJ6RBUJKI7S66 | id:lei-family: legal entity in this company's GLEIF ownership tree (LEI 549300QCJ6RBUJKI7S66) | GLEIF |
| EIN | 352528215 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001412486 | SEC EDGAR / IRS |
| CUSIP | 19188J409 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001412486 | SEC EDGAR |
former name (shown apart, not merged) (1)
- former nameBIOZONE PHARMACEUTICALS INC · EPA ECHO facilities
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Net income (loss) (fiscal year ended 2025-12-31) | -$8,831,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-21 11:39 UTC | Report an error |
| Total assets (at 2025-12-31) | $9,712,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-21 11:39 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $6,331,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-21 11:39 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $7,025,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-21 11:39 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 11:39 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 11:39 UTC | Report an error |
| State of incorporation | DE | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 11:39 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 11:39 UTC | Report an error |
| Business address | 19805 N. CREEK PARKWAY, BOTHELL, WA, 98011 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 11:39 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 11:39 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$8,192,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-21 11:39 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $12,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-21 11:39 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $1,505,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-21 11:39 UTC | Report an error |
| Form D total offering amount (D filed 2017-05-02) | $3,000,000 | 2017-05-02 | D | as filed | 2026-11-21 11:39 UTC | Report an error |
| Form D total amount sold (D filed 2017-05-02) | $3,000,000 | 2017-05-02 | D | as filed | 2026-11-21 11:39 UTC | Report an error |
| Form D industry group | Pharmaceuticals | 2017-05-02 | D | as filed | 2026-11-21 11:39 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2017-05-02 | D | as filed | 2026-11-21 11:39 UTC | Report an error |
| Form D date of first sale | 2017-04-25 | 2017-05-02 | D | as filed | 2026-11-21 11:39 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-16 · accession 0001493152-26-051938
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $105,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-16 | 0001493152-26-051938 | 2026-11-21 11:39 UTC | Report an error |
| Net income (loss) | -$3,444,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-16 | 0001493152-26-051938 | 2026-11-21 11:39 UTC | Report an error |
| Interest expense | -$15,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-16 | 0001493152-26-051938 | 2026-11-21 11:39 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-16 Filing 10-Q filed
- 2026-09-09 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-18 Filing 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-08-17 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-13 Filing 10-Q filed
- 2026-08-03 Filing 8-K filed: Item 1.01 material agreement; Item 3.02 unregistered equity sale; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-07-17 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-06-09 Filing 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-06-03 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-05-27 Filing DEFA14A filed
- 2026-05-27 Filing DEF 14A filed
- 2026-05-26 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-05-15 Filing 10-Q filed
- 2026-05-01 Filing EFFECT filed
- 2026-04-30 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-04-29 Filing CORRESP filed
- 2026-04-28 Filing UPLOAD filed
- 2026-04-23 Filing S-3 filed
- 2026-04-02 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-03-31 Filing 10-K filed
- 2026-03-31 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-03-13 Filing 8-K filed: Item 5.02 officer or director change
- 2026-03-09 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-02-19 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-01-15 Filing 8-K filed: Item 5.02 officer or director change
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | $376,139 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:39 UTC | Report an error |
| 2 | RENAISSANCE TECHNOLOGIES LLC | $188,609 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:39 UTC | Report an error |
| 3 | TWO SIGMA INVESTMENTS, LP | $184,148 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:39 UTC | Report an error |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | $80,034 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:39 UTC | Report an error |
| 5 | BlackRock, Inc. | $77,433 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:39 UTC | Report an error |
| 6 | CITADEL ADVISORS LLC | $47,374 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:39 UTC | Report an error |
| 7 | NEUBERGER BERMAN GROUP LLC | $33,480 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:39 UTC | Report an error |
| 8 | XTX Topco Ltd | $30,809 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:39 UTC | Report an error |
| 9 | JANE STREET GROUP, LLC | $27,049 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:39 UTC | Report an error |
| 10 | VANGUARD FIDUCIARY TRUST CO | $25,217 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:39 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
GLEIF OWNERSHIP TREE · ID TIER11. Subsidiaries
1 legal entity in the company's GLEIF ownership tree, joined by LEI (an official identifier).
- Cocrystal Pharma, Inc. · LEI 549300QCJ6RBUJKI7S66 · root
Exhibit 21 subsidiaries: not held yet.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
2 state and city records carry this company's exact name, from 2 sources. Possible matches only.
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchCocrystal Pharma, Inc. · exact legal name · sx:ctgov:hdb5262a05ab9c72f Compare
USAspending (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchCOCRYSTAL PHARMA, INC. · exact legal name · sx:usaspending:UY8UDESGRJ17 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1412486.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001412486. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.